Professional On-demand Education

Watch AML experts at the 2025 AAMDSIF Bone Marrow Failure Summit translate and discuss the latest science to advance patient outcomes. This session is moderated by Mikkael Sekeres, MD, MS from the University of Miami.

Session Topics:
HMA + Ven vs. 7+3 vs. liposomal cytarabine/daunorubicin for secondary AML   – Uma Borate, MD, Ohio State University
Using MRD to Make AML Treatment Decisions – Chris Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center 
Transplant Yes or No for Older Adults with AML: What factors make the decision? – Noa Holtzman, MD, University of Miami
The best approach for good-risk AML in Older Adults – Kah Poh Loh, MD, MS, FACCC, FASCO, University of Rochester

Watch PNH experts at the 2025 AAMDSIF Bone Marrow Failure Summit tackle the latest science and research on choosing the optimal complement inhibition strategy in PNH. This session is moderated by Phillip Scheinberg, MD from Hopital A Beneficencia in  Sao Paulo, Brazil.

Session Topics:

Factor B inhibitor – Regis Peffault deLatour, MD, PhD, Hopital Saint-Louis, Paris
Alternate C5 inhibitors - Austin Kulasekararaj, Kings College, London
Masp-3 inhibitor – Morag Griffin, MBChB, FRCPath, St. James University Hospital, Leeds, UK
C3 inhibitors - Carlos DeCastro, MD, Duke University

This symposium session highlights key strategies for fostering inclusivity in clinical research. Presentations cover the benefits and challenges of decentralized clinical trials, the critical role of translating consent documents for patients with limited English proficiency, and FDA initiatives to promote diversity. This video provides actionable insights into creating equitable opportunities for all participants in clinical trials.

This symposium session provides updates on the most recent advances in the pathophysiology diagnosis and clinical management of MDS and AML.

This symposium session explores the multidisciplinary approach to patient care, featuring insights from a social worker, a physician, and a psychiatrist. The video highlights the emotional, physical, and mental health challenges faced by patients with bone marrow failure and the comprehensive strategies used to address them. Together, the experts discuss tailored care plans, support systems, and the importance of holistic care in improving patient outcomes and quality of life.

This symposium session features presentations on tackling critical challenges in patient care. Topics include the impact of structural racism and other factors on leukemia outcomes, strategies to enhance care for older patients, and PCORI projects advancing diversity, equity, and inclusion (DEI) priorities. This video offers forward-thinking solutions to improve health equity and patient outcomes.

This symposium session provides updates on the most recent advances in the pathophysiology diagnosis and clinical management of aplastic anemia and PNH.

The biennial Symposium will bring together physicians treating these diseases; laboratory researchers studying genetics, genomics, and pathophysiology of bone marrow failure; and clinical investigators to discuss current areas of consensus and controversy, share recent research results, and identify the highest-priority directions for basic and clinical research to advance the field.
Symposium Co-Chairs: Richard Stone, MD and Neal Young, MD.

Session Co-Chairs Include:

• Genetics and Genomics – Daria Babushok, MD, PhD and Marcin Wlodarski, MD, PhD
• Clonality in acquired BMF, PNH, and VEXAS – Emma Groarke, MD and Kohei Hosokawa, MD, PhD
• Advances in PNH – Rodrigo Calado, MD, PhD  and Antonio Risitano, MD, PhD
• Transplantation for Marrow Failure – Amy DeZern, MD, MHS and Michael Pulsipher, MD
• Non-Transplant Therapies for Marrow Failure – Tim Olson, MD and Bhavisha Patel, MD
• Pathophysiology of MDS and Secondary AML – Jarek Maciejewski, MD, PhD, David Sallman, MD and Matthew Walter MD
• Treatments for MDS and Secondary AML – Andrew Brunner, MD and Jacqueline Garcia, MD
• MDS Classification and Prognosis – Robert Hasserjian, MD and Amer Zeidan, MD

This complimentary CME satellite symposium provided an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with AA, PNH, MDS, AML, MPN, and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

By participating, you will be able to:

Describe risk factors and implications of clonal hematopoiesis and potential strategies to modify the natural history of clonal hematopoiesis.
Outline best available evidence in managing patients with PNH.
Formulate appropriate evaluation and management strategies for patients with aplastic anemia and other bone marrow failure conditions.
Critically review the MDS diagnostic criteria in light of recent changes in disease nomenclature and describe expanding treatment strategies for low-risk and high-risk MDS.
Describe the new diagnostic criteria for AML and how to make personalized treatment decisions in patients with AML.  
Critically appraise the indications, efficacy, and adverse events for the expanding treatment options for patients with myeloproliferative neoplasms.
Synthesize current research on the role of cellular therapies in AML and their future potential.
Who Should View?
The satellite symposium is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians, nurses, advanced practice nurses, physician assistants and allied health care professionals treating patients with MDS, AML and myeloid malignancies. In addition, members of patient advocacy groups will benefit from this program.

This was a Friday Satellite Symposium organized by the Cleveland Clinic Taussig Cancer Institute and the Aplastic Anemia and MDS International Foundation, Inc., preceding the 65th ASH Annual Meeting and Exposition. ASH Annual Meeting registration is not required to participate in the symposium.
 

This symposium provides updates on the most recent advances in the pathophysiology, diagnosis and clinical management of bone marrow failure diseases, including aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), secondary acute myeloid leukemia (AML) and hematopoietic stem cell transplantation. Panel discussions will address the current gaps in patient care for each of these diseases, including: 

Diversifying clinical trial enrollment 
Addressing barriers to care – ageism, geographic and cultural challenges, delays in diagnosis, genetic profiling, long term supportive care 
Assessing quality of life issues and shared decision-making 
Target audience: Physicians, APPs, NPs, nurses and social workers.  

Since it was founded in 1983, AAMDSIF has partnered with clinicians and researchers to identify knowledge gaps in diagnosing and treating bone marrow failure and the research priorities needed to advance the field.
In honor of the AAMDSIF 40th Anniversary, this hybrid Summit will convene leading international experts in bone marrow failure to review significant advances in diagnosis and treatment and to determine future priorities for translational research.

PROGRAM HIGHLIGHTS:
Thursday, October 26, 2023 | 1pm - 8.30pm
Keynote Address: Progress in the Understanding of Bone Marrow Failure Since 1983
David Steensma, MD, FACP
Panel Sessions: Advances in Science and Treatment
Aplastic Anemia Panel
Moderator: Amy DeZern, MD, MHS, Johns Hopkins University
PNH Panel
Moderator: Carlos DeCastro, MD, Duke University
MDS Panel
Moderator: Olatoyosi Odenike, MD, University of Chicago
Reception and Poster Session
40th Anniversary Dinner Honoring Scientific Leaders in Bone Marrow Failure
AAMDSIF Lifetime Achievement in Science Awards
AAMDSIF Research Grantees
Friday, October 27, 2023 | 8am - 1.30pm
Pipeline Reports
Panel Session: The Future of Clinical Trials
Moderator: Mikkael Sekeres, MD, MS, University of Miami
Panel Session: Priorities for Future Research
Moderator: Timothy Graubert, MD, Massachusetts General Hospital
Summary Remarks
Olatoyosi Odenike, MD, AAMDSIF Medical Advisory Board Vice Chair

— CME WEBINAR | AFTER THE RESULTS — 
MDS Risk Stratification and Curative Treatment: The Expanding Role of HCT with IPSS-M 

Now available On-Demand
Earn up to 1.0 CME/CE credits* 
Learn from transplant and hematology/oncology experts in a discussion on the current state of HCT eligibility and when to consider HCT for patients with MDS. They highlight results from recently published studies on the International Prognostic Scoring System (IPSS) evolving to the inclusion of molecular disease markers (IPSS-M), referral patterns for HCT in MDS, and the latest consensus guidelines for the use of HCT in treating MDS. They also discuss how advances in HCT facilitate improved survival and preserve quality of life. 
WEBINAR PANELISTS: 
•Robert P. Hasserjian, MD 
Professor of Pathology - Massachusetts General Hospital/ Harvard Medical School 
•Andrew Brunner, MD
Assistant in Medicine, Division of Hematology/Oncology - Massachusetts General Hospital
Assistant Professor - Harvard Medical School 
•Bart L. Scott, MD
Professor, Transplantation Program, Clinical Research Division - Fred Hutch Cancer Center 
•Steven Devine, MD (moderator) 
Chief Medical Officer - NMDP/Be The Match
Associate Scientific Director - CIBMTR-NMDP/Be The Match 
 

ACCREDITED PROVIDER 
This activity is jointly provided by The France Foundation and the National Marrow Donor Program (NMDP)/Be The Match. 

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the NMDP/Be The Match. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

CREDIT DESIGNATION 

Physicians: The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses: The France Foundation designates this activity for 1.0 contact hours. 

All other healthcare professionals completing this course will be issued a statement of participation.  
For additional CME/CE information and disclosures, click here. 
 

Watch experts Régis Peffault de Latour, Alicia Rovó, and Phillip Scheinberg as they discuss aplastic anemia diagnosis and treatment options supported by patient cases. Watch the full webcast on Demand or select an individual presentation.

A Thread To Pull: Unraveling the Complexities of Myeloid Malignancies

This complimentary CME satellite symposium that provides an in-depth and up-to-date review of research related to biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Complement Regulation and Unmet Needs in the Treatment of Paroxysmal Nocturnal Hemoglobinuria 
 
Watch now on-demand
 
Featured Speakers 
 

Dr. Satheeth Chonat, M.D 
Assistant Professor, Pediatric Hematology 
Emory University School of Medicine 
Children’s Healthcare of Atlanta

Dr. Carlos de Castro  
Professor of Medicine 
Department of Medicine, Division of Hematologic Malignancies & Cell Therapy 
Duke University 
Theresa Elgin 
Patient Participant 

Learning Objectives:

• Describe strategies to decrease delays in the diagnosis of PNH
• Review existing and emerging therapeutics agents for PNH that target the complement cascade
• Discuss management of persistent challenges experienced by patients with PNH that impact quality of life
• Identify special circumstances that require counseling of patients with PNH